top of page
Create Your First Project
Start adding your projects to your portfolio. Click on "Manage Projects" to get started
Centessa Pharmaceuticals
Date
December 2022
SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data. Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Entry Price: 3.50
bottom of page